{
    "nct_id": "NCT02703636",
    "title": "A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch With 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - 23) Switched Directly From Holinesterase Inhibitors (Donepezil, Galantamine)",
    "status": "COMPLETED",
    "last_update_time": "2019-08-05",
    "description_brief": "To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's disease (AD) patients who failed to benefit from other cholinesterase inhibitors (ChEIs).",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "In total, 147 patients were screened for the study. 129 completed screening and 18 discontinued from screening. 118 patients were enrolled and the remaining 11 patients discontinued at baseline.\n\nAll 118 enrolled patients received study treatment. 102 completed the study and 16 discontinued",
            "recruitmentDetails": "The full analysis set (FAS) included all patients who received at least one dose of study treatment and had at least a baseline and any post-baseline assessment on treatment.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Rivastigmine Patch",
                    "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "118"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "102"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "16"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "14"
                                }
                            ]
                        },
                        {
                            "type": "Study stopped by sponsor",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "FAS",
            "groups": [
                {
                    "id": "BG000",
                    "title": "Rivastigmine Patch",
                    "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "118"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "76.4",
                                            "spread": "6.43"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "71"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "47"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race/Ethnicity, Customized",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "Asian",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "117"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Caucasian",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "MMSE Total Score: Change From Baseline to Week 8 and Week 24 (Full Analysis Set)",
                    "description": "Evaluation of the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of MMSE in mild to moderate Alzheimer's disease (AD) patients who failed to benefit from other cholinesterase inhibitors (ChEIs)\n\nThe MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.\n\nAbbreviated Scale title: Mini Mental State Evaluation Minimum Score: 0 Maximum score: 30 Higher score indicated better cognitive function",
                    "populationDescription": "The full analysis set (FAS) included all patients who received at least one dose of study treatment and had at least a baseline and any post-baseline assessment on treatment",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "baseline, weeks 8 and 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "118"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "118"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.33",
                                            "spread": "3.80"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "change at week 8",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "117"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.29",
                                            "spread": "2.17"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "change at week 24",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "102"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.36",
                                            "spread": "2.64"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000"
                            ],
                            "nonInferiorityType": "OTHER",
                            "nonInferiorityComment": "The MMRM model contained visit as a fixed effect, baseline MMSE score as a covariate and patient as a random effect.",
                            "pValue": "0.1750",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.35",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.87",
                            "ciUpperLimit": "0.16",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.259",
                            "estimateComment": "change at week 24"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "MMSE Total Score: Change From Baseline to Week 8 and Week 24",
                    "description": "Evaluation of the safety, tolerability of rivastigmine patch with 1-step titration for up to 24 weeks.\n\nPer Protocol, The MMSE is a brief, practical screening test for cognitive dysfunction. The MMSE consists of 2 parts: language (time orientation, registration and attention) and performance (recall, response to written/verbal commands, writing ability and reproduction of complex polygons), and the total possible score is 30. Lower score indicates more severe impairment. It is the most common and simple cognitive scale for Alzheimer's disease.\n\nUnabbreviated Scale : MMSE - Mini Mental State Evaluation:\n\nMinimum values - 0 Maximum value - 30 Higher Value means a better outcome\n\nPositive change score from baseline indicates improvement in cognitive function",
                    "populationDescription": "Per Protocol Set (PPS): The per protocol set includes all patients in the FAS who had only 1 step titration without any major deviations from the protocol procedures",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "baseline, weeks 8 and 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "118"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "112"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.24",
                                            "spread": "3.84"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 8",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "112"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.33",
                                            "spread": "2.19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 24",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "98"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.32",
                                            "spread": "2.63"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline to Week 8 in Mini-Mental State Examination (MMSE) Total Score",
                    "description": "Evaluation of the efficacy of rivastigmine patch with 1-step titration measured as the MMSE score at week 8 for patients who had 1-step titration\n\nMMSE total score: change from baseline to Week 8 and Week 24 for patients who had 1-step titration\n\nUnabbreviated Scale : MMSE - Mini Mental State Evaluation:\n\nMinimum values - 0 Maximum value - 30 Higher Value means a better outcome\n\nPositive change score from baseline indicates better outcome",
                    "populationDescription": "FAS",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "baseline and week 8",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "114"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.25",
                                            "spread": "3.82"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 8",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.31",
                                            "spread": "2.18"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Neuropsychiatric Inventory - 10 Item (NPI-10) Score From Baseline to Week 8 and Week 24",
                    "description": "Evaluation of the efficacy of rivastigmine patch with 1-step titration measured as the Neuropsychiatric Inventory - 10 Item (NPI-10) score at week 8 and week 24.\n\nPer protocol, Neuropsychiatric The NPI-10 total score is a sum of the 10 items, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and all domains are equally weighted for the total score (thus the range for the total score is 0 to 120).\n\nA higher score indicates more severe impairment.\n\nNeuropsychiatry Inventory - 10 Minimum Score = 0 Maximum Score = 120\n\nHigher Score indicates worse outcome",
                    "populationDescription": "FAS The number of participants analysed per row differs from overall number of participants because this is based on available data and patient continuation/discontinuation during that respective study period.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "baseline, week 8, week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "118"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "118"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "11.43",
                                            "spread": "11.15"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 8",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "116"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.81",
                                            "spread": "8.81"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 24",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "102"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.89",
                                            "spread": "11.10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in QOL-AD Score From Baseline to Week 24",
                    "description": "Evaluation of the efficacy of rivastigmine patch with 1-step titration measured as QOL-AD score at week 24.\n\nUnabbreviated Scale Name: Quality of Life - Alzheimer's Disease Minimum Score = 13 Maximum Score = 52\n\nHigher value indicates a better outcome\n\nQOL-AD is a 13-item questionnaire to assess the quality of life of Alzheimer's patients from the perspectives of patients and their caregivers. It covers several aspects, for example, the perception of health status, mood, functional capacity, personal relationships and leisure, financial situation, and life as a whole. Each item is quantified using a Likert scale with score one classified as poor, and score four as excellent where total scores range from 13 to 52. A lower score indicates more severe impairment.",
                    "populationDescription": "FAS\n\nThe number of participants analysed per row differs from overall number of participants because this is based on available data and patient continuation/discontinuation during that respective study period.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "baseline and week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "118"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "baseline - Patient's assessment",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "118"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "34.37",
                                            "spread": "5.78"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 24 - Patient's assessment",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "102"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.34",
                                            "spread": "5.32"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "baseline - Caregiver's assessment",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "118"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "28.75",
                                            "spread": "5.74"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 24 - Caregiver's assessment",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "103"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.16",
                                            "spread": "5.42"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in J-CGIC Score From Baseline and at Week 24",
                    "description": "Evaluation of the efficacy of rivastigmine patch with 1-step titration measured as the The Japanese-Clinical Global Impression of Change (J-CGIC) score at baseline and week 24\n\nJ-CGIC is a 7-grade investigator's impression scale: 1. Markedly improved, 2. Improved, 3. Slightly improved, 4. No change, 5. Slightly aggravated, 6. Aggravated, 7. Markedly aggravated\n\nAt week 24, 103 patients had available data\n\nTotal score is in the 0 to 56 range. Higher score means more severe impairment.\n\nUnabbreviated scale title: Japanese -Cinical Global Impression of Change Minimum Score - 1 Maximum Score - 7",
                    "populationDescription": "FAS",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "baseline and week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "103"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Patients without worsening, total",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "91"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Patients with improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "48"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Patients with worsening, total",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Markedly improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Slightly improved",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "No change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "43"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Slightly aggravated",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "11"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Aggravated",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Markedly aggravated",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Unassessable",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in as Modified Crichton Scale Score From Baseline to Week 4, 8, 16 and 24",
                    "description": "Evaluation of the efficacy of rivastigmine patch with 1-step titration measured as Modified Crichton Scale score week 4, week 8, week 16, and week 24.\n\nModified Crichton Scale that assess basic activation of daily living, communication functions, and quality of life The following 7 items will be evaluated by caregiver. Total score is in the 0 to 56 range. Higher score means more severe impairment.\n\nUnabbreviated Scale Title: Modified Crichton scale Minimum score = 0 Maximum Score = 56 Higher score indicates worse outcome",
                    "populationDescription": "FAS\n\nThe number of participants analysed per row (modified crichton scale) differs from overall number of participants because this is based on available data and patient continuation/discontinuation during that respective study period.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "scores on a scale",
                    "timeFrame": "baseline, weeks 4, 8, 16, 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "118"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "baseline",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "118"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18.38",
                                            "spread": "9.41"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 4",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "117"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.41",
                                            "spread": "5.44"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 8",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "116"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.55",
                                            "spread": "6.58"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 16",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "108"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.04",
                                            "spread": "6.94"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "week 24",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "103"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.23",
                                            "spread": "6.69"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Formulation Usability Questionnaire Form Score up to Week 24",
                    "description": "Evaluation of the formulation usability of rivastigmine patch for up to 24 weeks as measured by the formulation usability questionnaire answered by caregiver.\n\nThe Formulation usability preference questionnaire had been used to compare the previous oral AD drugs versus the patch The caregiver selects one of the following answers (1. Very easy to use, 2. Easy to use, 3. No change, 4. Not easy to use, 5. Not easy to use at all, 6. Unknown).\n\nThis questionnaire data is used to assess if the usability of rivastigmine patch was preferred by the majority (\\> 50%) of AD patient caregivers or not.\n\nUnabbreviated Questionnaire title:\n\nFormulation Usability questionnaire Minimum Score = 1 Maximum Score = 6\n\nA higher score indicates its not easy to use and worse outcome.",
                    "populationDescription": "FAS",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Up to week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "117"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Very easy to use",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Easy to use",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "26"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "No change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Not easy to use",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "36"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Not easy to use at all",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "up to week 24",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Exelon/Rivastigmine Patch",
                    "description": "Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and was up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 118,
                    "seriousNumAffected": 5,
                    "seriousNumAtRisk": 118,
                    "otherNumAffected": 57,
                    "otherNumAtRisk": 118
                }
            ],
            "seriousEvents": [
                {
                    "term": "Ileus",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Pancreatitis acute",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Herpes zoster",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Dehydration",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Hypoglycaemia",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Arthralgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Breast cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 118
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Application site erythema",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Application site pruritus",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 12,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Dermatitis contact",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 18,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Erythema",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Pruritus",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 118
                        }
                    ]
                },
                {
                    "term": "Rash",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA (21.0)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 118
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."
            },
            "pointOfContact": {
                "title": "Study Director",
                "organization": "Novartis Pharmaceuticals",
                "email": "novartis.email@novartis.com",
                "phone": "+1 (862) 778-8300"
            }
        }
    },
    "target_category": "Cognitive enhancer",
    "drug": [
        "Rivastigmine transdermal patch (Exelon patch)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests rivastigmine delivered as a transdermal patch, with the primary outcome being change in MMSE at 24 weeks (a cognitive endpoint). Rivastigmine is a cholinesterase inhibitor that increases acetylcholine availability and is approved for symptomatic treatment of mild-to-moderate Alzheimer\u2019s disease rather than as a disease-modifying therapy. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Act: Key extracted details \u2014 intervention: rivastigmine patch (transdermal), open-label 24-week study in mild\u2013moderate AD (MMSE 10\u201323), outcome: change in MMSE (cognition); patient population: switched from other cholinesterase inhibitors. Rivastigmine is a small-molecule pseudo\u2011irreversible inhibitor of acetylcholinesterase and butyrylcholinesterase and has demonstrated modest cognitive benefits on scales including MMSE and ADAS\u2011Cog in randomized trials of AD. \ue200cite\ue202turn0search6\ue202turn0search4\ue201",
        "Reflect: Classification check \u2014 by the definitions given, this is not a biologic (rivastigmine is a small molecule), and it targets cholinergic neurotransmission to improve cognition symptomatically rather than targeting core AD pathology (amyloid/tau) or primarily treating neuropsychiatric symptoms. Therefore the correct category is \"Cognitive enhancer.\" Supporting sources: clinical trial and review evidence for rivastigmine patch efficacy on cognition and mechanism of action. \ue200cite\ue202turn0search0\ue202turn0search8\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests rivastigmine (Exelon patch), a cholinesterase inhibitor that increases synaptic acetylcholine by inhibiting acetylcholinesterase (and butyrylcholinesterase). That mechanism modulates cholinergic neurotransmission to produce symptomatic cognitive benefit rather than targeting core AD pathologies (amyloid or tau). \ue200cite\ue202turn0search6\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 drug: rivastigmine transdermal patch (Exelon patch); indication/context: symptomatic treatment of mild\u2013moderate AD with cognitive endpoint (MMSE change); mechanism: reversible/pseudo\u2011irreversible inhibition of acetylcholinesterase and butyrylcholinesterase increasing acetylcholine availability. These facts align rivastigmine with CADRO\u2019s neurotransmitter modulation domain. \ue200cite\ue202turn0search5\ue202turn0search8\ue201",
        "Reflect: Classification check \u2014 rivastigmine is a small\u2011molecule cholinesterase inhibitor that acts on cholinergic neurotransmission (not amyloid, tau, inflammation, or other CADRO categories). Therefore the most specific CADRO match is D) Neurotransmitter Receptors (covers interventions that modulate neurotransmitter systems to improve cognition). This is consistent with clinical reviews and product information describing symptomatic cognitive benefit. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web search results (sources used): 1) StatPearls \u2014 rivastigmine mechanism: inhibits AChE and BuChE, transdermal formulations and dosing details. \ue200cite\ue202turn0search6\ue201 2) CenterWatch / Exelon Patch summary \u2014 mechanism (cholinesterase inhibitor), clinical use and dosing notes. \ue200cite\ue202turn0search5\ue201 3) PubMed reviews \u2014 clinical trial evidence of cognitive benefit in mild\u2013moderate AD and review of rivastigmine pharmacology. \ue200cite\ue202turn0search0\ue202turn0search4\ue201 4) Novartis Exelon Patch product/label information \u2014 regulatory/label updates and safety considerations. \ue200cite\ue202turn0search2\ue202turn0search3\ue201"
    ]
}